Enliven Therapeutics, Inc. 4

CFO Benjamin Hohl of Enliven Therapeutics exercised options for 1,072 shares at $2.48 and sold 6,018 shares of ELVN common stock around $50–$54 per share, ending with 46,054 shares owned.

On July 17, 2026, Enliven Therapeutics, Inc. CFO Benjamin Hohl exercised a stock option for 1,072 shares of common stock at $2.48 per share and simultaneously sold a total of 6,018 shares of common stock in multiple open-market transactions at weighted average prices between approximately $49.97 and $53.87 per share under a pre-established Rule 10b5-1 trading plan. The option exercise (coded “M”) added 1,072 shares to his holdings, while the sales (coded “S”) of 324, 369, 2,564, 2,638, and 123 shares, respectively, reduced his direct ownership from 52,072 shares to 46,054 shares of common stock. The option was already fully vested and exercisable, and after these transactions Hohl continues to hold a meaningful direct equity stake in the company, valued in the low seven figures using the contemporaneous market prices as a proxy.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

fda

Accession

0001882764-26-000006

Alert Tier

6